XTMAB-16-202: A Long-term Multicenter Open-label Study to Evaluate the Long-term Safety and Durability of Effect of XTMAB-16 in Patients With Pulmonary Sarcoidosis With or Without Extra-pulmonary Involvement Grant uri icon

abstract

  • This open-label study is conducted to assess the long-term safety and tolerability as well as to confirm the efficacy (durability/maintenance of effect) of XTMAB-16 in participants with pulmonary sarcoidosis with or without extra-pulmonary involvement by providing participants in the XTMAB-16-201 clinical study access or continued access to XTMAB-16 treatment prior to the product potentially being available commercially.

date/time interval

  • November 2023 - August 2025